Last reviewed · How we verify

Telbivudine (Standard of Care)

Nanfang Hospital, Southern Medical University · FDA-approved active Small molecule

Telbivudine (Standard of Care) is a Nucleoside reverse transcriptase inhibitor (NRTI) Small molecule drug developed by Nanfang Hospital, Southern Medical University. It is currently FDA-approved for Chronic hepatitis B infection.

Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.

Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme. Used for Chronic hepatitis B infection.

At a glance

Generic nameTelbivudine (Standard of Care)
SponsorNanfang Hospital, Southern Medical University
Drug classNucleoside reverse transcriptase inhibitor (NRTI)
TargetHepatitis B virus reverse transcriptase
ModalitySmall molecule
Therapeutic areaVirology / Hepatology
PhaseFDA-approved

Mechanism of action

Telbivudine is a thymidine nucleoside analog that is phosphorylated intracellularly and incorporated into the growing DNA chain of hepatitis B virus, causing chain termination and preventing viral replication. It selectively inhibits HBV reverse transcriptase with high potency and a high genetic barrier to resistance compared to some other nucleoside analogs.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Telbivudine (Standard of Care)

What is Telbivudine (Standard of Care)?

Telbivudine (Standard of Care) is a Nucleoside reverse transcriptase inhibitor (NRTI) drug developed by Nanfang Hospital, Southern Medical University, indicated for Chronic hepatitis B infection.

How does Telbivudine (Standard of Care) work?

Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.

What is Telbivudine (Standard of Care) used for?

Telbivudine (Standard of Care) is indicated for Chronic hepatitis B infection.

Who makes Telbivudine (Standard of Care)?

Telbivudine (Standard of Care) is developed and marketed by Nanfang Hospital, Southern Medical University (see full Nanfang Hospital, Southern Medical University pipeline at /company/nanfang-hospital-southern-medical-university).

What drug class is Telbivudine (Standard of Care) in?

Telbivudine (Standard of Care) belongs to the Nucleoside reverse transcriptase inhibitor (NRTI) class. See all Nucleoside reverse transcriptase inhibitor (NRTI) drugs at /class/nucleoside-reverse-transcriptase-inhibitor-nrti.

What development phase is Telbivudine (Standard of Care) in?

Telbivudine (Standard of Care) is FDA-approved (marketed).

What are the side effects of Telbivudine (Standard of Care)?

Common side effects of Telbivudine (Standard of Care) include Myositis or muscle pain, Elevated creatine kinase, Lactic acidosis, Hepatitis flare, Fatigue.

What does Telbivudine (Standard of Care) target?

Telbivudine (Standard of Care) targets Hepatitis B virus reverse transcriptase and is a Nucleoside reverse transcriptase inhibitor (NRTI).

Related